Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Up 453.3% in June

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 938,810 shares, a growth of 453.3% from the June 15th total of 169,677 shares. Based on an average daily volume of 5,496,954 shares, the short-interest ratio is currently 0.2 days. Approximately 4.2% of the company’s shares are short sold.

Jupiter Neurosciences Price Performance

JUNS traded down $0.01 on Monday, reaching $0.18. 529,649 shares of the company traded hands, compared to its average volume of 3,563,838. The stock’s 50 day moving average price is $0.26 and its 200-day moving average price is $0.49. Jupiter Neurosciences has a 52-week low of $0.17 and a 52-week high of $3.33. The company has a market cap of $6.59 million, a price-to-earnings ratio of -0.67 and a beta of 1.73.

Jupiter Neurosciences (NASDAQ:JUNS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.23 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Jupiter Neurosciences presently has an average rating of “Sell”.

Institutional Trading of Jupiter Neurosciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vestor Capital LLC raised its holdings in shares of Jupiter Neurosciences by 144,607.2% during the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after acquiring an additional 970,314 shares in the last quarter. Yorkville Advisors Global LP purchased a new position in Jupiter Neurosciences in the fourth quarter valued at about $135,000. Geode Capital Management LLC grew its stake in Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after purchasing an additional 28,826 shares in the last quarter. Finally, Allen Capital Group LLC acquired a new position in Jupiter Neurosciences in the 4th quarter worth about $31,000.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.